Brainstorm Cell Therapeutics Inc. (BCLI)

BCLI Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	6.47	5.78	7.04	10.69	10.87	9.3
Research & Development	3.48	4.18	4.65	10.75	13.96	15.24
Operating Expenses	9.95	9.95	11.69	21.44	24.82	24.54
Operating Income	-9.95	-9.95	-11.69	-21.44	-24.82	-24.54
Interest Expense	-0.57	-0.53	-0.08	-0.28	-	-
Interest & Investment Income	-	-	-	-	0.55	0.08
Other Non Operating Income (Expenses)	-	0.18	0.15	4.53	-	-
Pretax Income	-10.52	-10.31	-11.62	-17.19	-24.28	-24.46
Net Income	-10.52	-10.31	-11.62	-17.19	-24.28	-24.46
Net Income to Common	-10.52	-10.31	-11.62	-17.19	-24.28	-24.46
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	11	9	5	3	2	2
Shares Outstanding (Diluted)	11	9	5	3	2	2
Shares Change	69.90%	84.58%	74.87%	17.99%	0.91%	21.22%
EPS (Basic)	-0.95	-1.11	-2.31	-5.99	-9.97	-10.14
EPS (Diluted)	-0.95	-1.11	-2.31	-5.99	-9.97	-10.20
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-	-6.98	-9.09	-20.48	-19.35	-26.6
Free Cash Flow Per Share	-	-0.75	-1.81	-7.13	-7.95	-11.03
EBITDA	-9.78	-9.75	-11.45	-21.17	-24.54	-24.28
D&A For EBITDA	0.17	0.2	0.24	0.27	0.29	0.26
EBIT	-9.95	-9.95	-11.69	-21.44	-24.82	-24.54

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error